Medtronic (Minneapolis) in mid-June received FDA approval of its Attain StarFix OTW (over-the-wire) lead. The company said it's the first active fixation left-heart lead for cardiac resynchronization therapy (CRT) and that the lead has demonstrated a 0% chronic (meaning more than one day post-implant) dislodgement rate.

Medtronic's left-heart CRT lead is okayed

Name: Relias Media
Price range: $

January 2, 2015

Reprints

Recognizing, Managing, and Reporting Pediatric Sexual Abuse and Assault
Eleventh Circuit Affirms Jury Verdict of $2.5 Million for Mesh Device Plaintiff Despite Close Call on Statute of Limitations
Indiana Appellate Court Allows Case to Proceed Against Doctor Accused of Improperly Accessing Patients’ Medical Records
Malpractice Insurance Rates Increasing After Stable Period
Clinical Decision Software Highly Effective in OR